Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185138 | 0.92 | KIF11 (0.39) | CYP2C9MAPTSMN1; SMN2BACE1ALDH1A1 | |
| SCHEMBL42458 | 0.88 | ALDH1A1 (0.56) | MAPTALDH1A1ALOX15MAPK1KMT2A | |
| SCHEMBL305335 | 0.86 | ALDH1A1 (0.39) | CYP2C9MAPTSMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL13839048 | 0.84 | CYP2C9 (0.47) | CYP2C9MAPTSMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL78396 | 0.84 | MAPT (0.48) | CYP2C9MAPTSMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL3290659 | 0.84 | CYP2C9 (0.47) | CYP2C9MAPTSMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL16858286 | 0.83 | CYP2C9 (0.43) | CYP2C9MAPTSMN1; SMN2BACE1ALDH1A1 | |
| SCHEMBL1751011 | 0.82 | CYP2C9 (0.46) | CYP2C9MAPTSMN1; SMN2BACE1PTPN5 | |
| SCHEMBL21886974 | 0.81 | CYP2C9 (0.44) | CYP2C9MAPTSMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL13840143 | 0.81 | MAPT (0.47) | CYP2C9MAPTSMN1; SMN2ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021136808-A1 | CONJUGATES UNDERGOING INTRAMOLECULAR REARRANGEMENTS | ASCENDIS PHARMA A/S (DK) | 2021-07-08 | — | — | WO | disclosed |
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | VERA THERAPEUTICS INC (US) | 2021-07-08 | — | — | US | disclosed |
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | NEUBASE THERAPEUTICS, INC. | 2019-02-21 | — | — | US | disclosed |
| US-20160367091-A9 | Personal Care Compositions Comprising a Di-Amido Gellant and Methods of Using | THE PROCTER & GAMBLE COMPANY | 2016-12-22 | — | — | US | disclosed |
| US-20160367091-A9 | Personal Care Compositions Comprising a Di-Amido Gellant and Methods of Using | THE PROCTER & GAMBLE COMPANY | 2016-12-22 | — | — | US | disclosed |
| EP-2365050-B1 | DI-AMIDO GELLANT FOR USE IN CONSUMER PRODUCT COMPOSITIONS | PROCTER & GAMBLE (US) | 2016-08-10 | — | — | EP | disclosed |
| US-9334465-B2 | Structuring using an external structurant and a cosmotrope | THE PROCTER & GAMBLE COMPANY (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334465-B2 | Structuring using an external structurant and a cosmotrope | THE PROCTER & GAMBLE COMPANY (US) | 2016-05-10 | — | — | US | disclosed |
| WO-2014099852-A1 | IMPROVED STRUCTURING USING AN EXTERNAL STRUCTURANT AND A COSMOTROPE | THE PROCTER & GAMBLE COMPANY (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20120151881-A1 | PROCESSES FOR MAKING FLUID DETERGENT COMPOSITIONS COMPRISING A DI-AMIDO GELLANT | FERNANDEZ PRIETO SUSANA (ES) | 2012-06-21 | — | — | US | disclosed |
| US-20120151881-A1 | PROCESSES FOR MAKING FLUID DETERGENT COMPOSITIONS COMPRISING A DI-AMIDO GELLANT | FERNANDEZ PRIETO SUSANA (ES) | 2012-06-21 | — | — | US | disclosed |
| US-8168579-B2 | Fluid detergent compositions comprising a di-amido gellant, and processes for making | THE PROCTER AND GAMBLE COMPANY (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168579-B2 | Fluid detergent compositions comprising a di-amido gellant, and processes for making | THE PROCTER AND GAMBLE COMPANY (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110224455-A1 | Di-Amido Gellant For Use In Consumer Product Compositions | THE PROCTER & GAMBLE COMPANY | 2011-09-15 | — | — | US | disclosed |
| US-20110220536-A1 | Fluid Detergent Compositions Comprising a Di-Amido Gellant, and Processes for Making | THE PROCTER & GAMBLE COMPANY | 2011-09-15 | — | — | US | disclosed |
| US-20110220536-A1 | Fluid Detergent Compositions Comprising a Di-Amido Gellant, and Processes for Making | THE PROCTER & GAMBLE COMPANY | 2011-09-15 | — | — | US | disclosed |
| US-20110224455-A1 | Di-Amido Gellant For Use In Consumer Product Compositions | THE PROCTER & GAMBLE COMPANY | 2011-09-15 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| WO-2009077173-A2 | DNA-ENCODED CHEMICAL LIBRARIES | PHILOCHEM AG (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | CYP2C9 4524/4885MAPT 2325/4885SMN1; SMN2 506/4885 |
| US-20110224455-A1 | Di-Amido Gellant For Use In Consumer Product Compositions | DAGLA, GNPAT, CDIPT | CYP2C9 555/4885MAPT 1057/4885SMN1; SMN2 3740/4885 |
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | AGO2, TARBP1, TPR | CYP2C9 4085/4885MAPT 2695/4885SMN1; SMN2 840/4885 |
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | CYP2C9 392/4885MAPT 3478/4885SMN1; SMN2 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.